These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 1302764)
1. A physiologically based pharmacokinetic model for nicotine and cotinine in man. Robinson DE; Balter NJ; Schwartz SL J Pharmacokinet Biopharm; 1992 Dec; 20(6):591-609. PubMed ID: 1302764 [TBL] [Abstract][Full Text] [Related]
2. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Yamazaki H; Horiuchi K; Takano R; Nagano T; Shimizu M; Kitajima M; Murayama N; Shono F Int J Environ Res Public Health; 2010 Sep; 7(9):3406-21. PubMed ID: 20948932 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. Scherer G; Jarczyk L; Heller WD; Biber A; Neurath GB; Adlkofer F Klin Wochenschr; 1988; 66 Suppl 11():5-11. PubMed ID: 3184779 [TBL] [Abstract][Full Text] [Related]
4. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802 [TBL] [Abstract][Full Text] [Related]
5. A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. Plowchalk DR; Andersen ME; deBethizy JD Toxicol Appl Pharmacol; 1992 Oct; 116(2):177-88. PubMed ID: 1412462 [TBL] [Abstract][Full Text] [Related]
6. Use of a physiologically-based pharmacokinetic model to explore the potential disparity in nicotine disposition between adult and adolescent nonhuman primates. Yang X; Naylor J; Matazel K; Goodwin A; Jacob CC; Bryant M; Loukotková L; Gamboa da Costa G; Chemerynski S; Deng-Bryant Y; Reissig C; Jackson K; Fisher J Toxicol Appl Pharmacol; 2020 Jan; 386():114826. PubMed ID: 31730783 [TBL] [Abstract][Full Text] [Related]
7. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Benowitz NL; Jacob P Clin Pharmacol Ther; 1993 Mar; 53(3):316-23. PubMed ID: 8453850 [TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modelling for Nicotine and Cotinine Clearance in Pregnant Women. Amice B; Ho H; Zhang E; Bullen C Front Pharmacol; 2021; 12():688597. PubMed ID: 34354586 [No Abstract] [Full Text] [Related]
9. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat. Gabrielsson J; Bondesson U J Pharmacokinet Biopharm; 1987 Dec; 15(6):583-99. PubMed ID: 3450843 [TBL] [Abstract][Full Text] [Related]
10. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Benowitz NL; Zevin S; Jacob P Br J Clin Pharmacol; 1997 Mar; 43(3):259-67. PubMed ID: 9088580 [TBL] [Abstract][Full Text] [Related]
11. Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. Liakoni E; St Helen G; Dempsey DA; Jacob P; Tyndale RF; Benowitz NL Drug Alcohol Depend; 2019 Nov; 204():107474. PubMed ID: 31521954 [TBL] [Abstract][Full Text] [Related]
12. A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans. Saylor K; Zhang C Toxicol Appl Pharmacol; 2016 Sep; 307():150-164. PubMed ID: 27473014 [TBL] [Abstract][Full Text] [Related]
13. A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. Teeguarden JG; Housand CJ; Smith JN; Hinderliter PM; Gunawan R; Timchalk CA Regul Toxicol Pharmacol; 2013 Feb; 65(1):12-28. PubMed ID: 23099439 [TBL] [Abstract][Full Text] [Related]
14. Nicotine and cotinine exposure from electronic cigarettes: a population approach. Vélez de Mendizábal N; Jones DR; Jahn A; Bies RR; Brown JW Clin Pharmacokinet; 2015 Jun; 54(6):615-26. PubMed ID: 25503588 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of nicotine and its metabolites I. Model development. Levi M; Dempsey DA; Benowitz NL; Sheiner LB J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):5-21. PubMed ID: 17206524 [TBL] [Abstract][Full Text] [Related]
16. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Kyerematen GA; Morgan ML; Chattopadhyay B; deBethizy JD; Vesell ES Clin Pharmacol Ther; 1990 Dec; 48(6):641-51. PubMed ID: 2249376 [TBL] [Abstract][Full Text] [Related]
17. Simulation and evaluation of nicotine intake during passive smoking: cotinine measurements in body fluids of nonsmokers given intravenous infusions of nicotine. Curvall M; Vala EK; Enzell CR; Wahren J Clin Pharmacol Ther; 1990 Jan; 47(1):42-9. PubMed ID: 2295218 [TBL] [Abstract][Full Text] [Related]
18. Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling. Thompson MD; Beard DA; Wu F J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):313-27. PubMed ID: 22639356 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers. Kochak GM; Sun JX; Choi RL; Piraino AJ Pharm Res; 1992 Nov; 9(11):1451-5. PubMed ID: 1475232 [TBL] [Abstract][Full Text] [Related]
20. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. Levi M; Dempsey DA; Benowitz NL; Sheiner LB J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):23-34. PubMed ID: 17206525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]